Mangoceuticals, Inc. Common Stock Net Assets
Mangoceuticals, Inc. Common Stock net assets. Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has net assets worth $12.52 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.17 Million) and total liabilities ($1.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MGRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.52 Million |
| % of Total Assets | 88.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 793.1 |
Net Assets of Mangoceuticals, Inc. Common Stock (2021–2025)
Net assets of Mangoceuticals, Inc. Common Stock from 2021 to 2025. This chart illustrates how Mangoceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Mangoceuticals, Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Net Assets for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Mangoceuticals, Inc. Common Stock from 2021 to 2025. For live market cap and overall valuation, see Mangoceuticals, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.20 Million | +8.99% |
| 2024-12-31 | $13.95 Million | +1699.93% |
| 2023-12-31 | $774.75K | +26.18% |
| 2022-12-31 | $614.03K | +3772.43% |
| 2021-12-31 | $-16.72K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mangoceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4062977900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mangoceuticals, Inc. Common Stock Net Assets Breakdown (December 2025)
Mangoceuticals, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.59K | 0.01% |
| Other Comprehensive Income | $-2.76K | -0.02% |
| Other Components | $55.85 Million | 367.42% |
| Total Equity | $15.20 Million | 100.00% |
Mangoceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marvel Biosciences Corp
V:MRVL
|
$5.04 Million |
|
Throgmorton Trust Plc
LSE:THRG
|
$5.04 Million |
|
VITAL BATTERY METALS INC
F:C0O
|
$5.04 Million |
|
Gix Internet Ltd
TA:GIX
|
$5.05 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
$5.03 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
$5.03 Million |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
$5.03 Million |
|
Quantum Genomics SA
PA:ALQGC
|
$5.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mangoceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,946,129 to 15,200,547, a change of 1,254,418 (9.0%).
- Net loss of 20,643,455 reduced equity.
- New share issuances of 4,725,355 increased equity.
- Other comprehensive income increased equity by 7,085.
- Other factors increased equity by 17,165,433.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.64 Million | -135.81% |
| Share Issuances | $4.73 Million | +31.09% |
| Other Comprehensive Income | $7.08K | +0.05% |
| Other Changes | $17.17 Million | +112.93% |
| Total Change | $- | 8.99% |
Book Value vs Market Value Analysis
This analysis compares Mangoceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.01 | $0.23 | x |
| 2022-12-31 | $0.53 | $0.23 | x |
| 2023-12-31 | $0.54 | $0.23 | x |
| 2024-12-31 | $7.05 | $0.23 | x |
| 2025-12-31 | $1.51 | $0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mangoceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4526.86%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.06x
- Recent ROE (-135.81%) is above the historical average (-342.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.03K |
| 2022 | -325.40% | -22352.11% | 0.01x | 1.63x | $-2.06 Million |
| 2023 | -1189.08% | -1259.40% | 0.70x | 1.36x | $-9.29 Million |
| 2024 | -62.43% | -1413.60% | 0.04x | 1.10x | $-10.10 Million |
| 2025 | -135.81% | -4526.86% | 0.03x | 1.06x | $-22.16 Million |
Industry Comparison
This section compares Mangoceuticals, Inc. Common Stock's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $579,648,737
- Average return on equity (ROE) among peers: -67.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mangoceuticals, Inc. Common Stock (MGRX) | $12.52 Million | 0.00% | 0.13x | $5.03 Million |
| Aclarion Inc (ACON) | $970.06K | -720.88% | 1.19x | $1.14 Million |
| American Well Corp (AMWL) | $1.25 Billion | -18.01% | 0.10x | $133.17 Million |
| Heartbeam Inc (BEAT) | $63.68 Million | -15.38% | 0.96x | $25.09 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-1.01 Million | 0.00% | 0.00x | $5.56 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $1.65 Billion | -1.09% | 2.59x | $10.63 Billion |
| Carlsmed, Inc. (CARL) | $-46.13 Million | 0.00% | 0.00x | $408.18 Million |
| CareCloud, Inc. (CCLD) | $38.87 Million | -5.50% | 0.23x | $74.79 Million |
| Certara Inc (CERT) | $1.05 Billion | -5.29% | 0.49x | $1.12 Billion |
| CareMax Inc (CMAX) | $4.95 Million | 121.69% | 3.92x | $381.50 |
| Claritev Corporation (CTEV) | $1.79 Billion | -32.00% | 3.12x | $409.15 Million |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more